Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pralsetinib

(pral-SEH-tih-nib)
A drug used to treat adults with non-small cell lung cancer that has a RET fusion gene and has spread to other parts of the body and adults and children aged 12 years and older with thyroid cancer that has a RET fusion gene, has spread, and needs treatment with systemic therapy. This includes patients whose thyroid cancer did not respond to radioactive iodine. It is also being studied in the treatment of other types of cancer. Pralsetinib blocks certain proteins made by the RET fusion gene, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Gavreto.
More Information
Search NCI's Dictionary of Cancer Terms